E
71.30
1.21 (1.73%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Edwards Lifesciences Corporatio | Bearish | Bearish |
Stockmoo Score
-0.5
|
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Core |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 106.00 (Citigroup, 48.67%) | Buy |
| Median | 79.50 (11.50%) | |
| Low | 70.00 (Stifel, -1.82%) | Hold |
| 70.00 (TD Cowen, -1.82%) | Hold | |
| 70.00 (Baird, -1.82%) | Hold | |
| Average | 81.38 (14.14%) | |
| Total | 7 Buy, 9 Hold | |
| Avg. Price @ Call | 62.16 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 26 Jul 2024 | 90.00 (26.23%) | Buy | 62.37 |
| Goldman Sachs | 26 Jul 2024 | 91.00 (27.63%) | Buy | 62.37 |
| B of A Securities | 25 Jul 2024 | 75.00 (5.19%) | Hold | 59.70 |
| Baird | 25 Jul 2024 | 70.00 (-1.82%) | Hold | 59.70 |
| Canaccord Genuity | 25 Jul 2024 | 77.00 (7.99%) | Hold | 59.70 |
| Deutsche Bank | 25 Jul 2024 | 85.00 (19.21%) | Buy | 59.70 |
| Evercore ISI Group | 25 Jul 2024 | 76.00 (6.59%) | Hold | 59.70 |
| 02 Jul 2024 | 91.00 (27.63%) | Hold | 91.23 | |
| JP Morgan | 25 Jul 2024 | 72.00 (0.98%) | Hold | 59.70 |
| Oppenheimer | 25 Jul 2024 | 90.00 (26.23%) | Buy | 59.70 |
| Piper Sandler | 25 Jul 2024 | 73.00 (2.38%) | Hold | 59.70 |
| RBC Capital | 25 Jul 2024 | 85.00 (19.21%) | Buy | 59.70 |
| Stifel | 25 Jul 2024 | 70.00 (-1.82%) | Hold | 59.70 |
| TD Cowen | 25 Jul 2024 | 70.00 (-1.82%) | Hold | 59.70 |
| Truist Securities | 25 Jul 2024 | 82.00 (15.01%) | Hold | 59.70 |
| 16 Jul 2024 | 110.00 (54.28%) | Buy | 87.73 | |
| Wells Fargo | 25 Jul 2024 | 90.00 (26.23%) | Buy | 59.70 |
| Citigroup | 10 Jul 2024 | 106.00 (48.67%) | Buy | 93.78 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SZYMAN CATHERINE M. | 68.75 | 68.75 | 5,380 | 369,875 |
| Aggregate Net Quantity | 5,380 | |||
| Aggregate Net Value ($) | 369,875 | |||
| Aggregate Avg. Buy ($) | 68.75 | |||
| Aggregate Avg. Sell ($) | 68.75 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SZYMAN CATHERINE M. | Officer | 03 Sep 2024 | Acquired (+) | 10,910 | 68.75 | 750,063 |
| SZYMAN CATHERINE M. | Officer | 03 Sep 2024 | Disposed (-) | 5,530 | 68.75 | 380,188 |
| Date | Type | Details |
|---|---|---|
| 03 Sep 2024 | Announcement | Edwards Lifesciences Completes Sale of Critical Care |
| 31 Aug 2024 | Announcement | CORRECTING and REPLACING First All-Female TAVI Trial Shows Excellent Outcomes for Women Receiving Edwards Valves |
| 21 Aug 2024 | Announcement | Edwards Lifesciences to Present at the 2024 Wells Fargo Healthcare Conference |
| 24 Jul 2024 | Announcement | Edwards Lifesciences Reports Second Quarter Results |
| 24 Jul 2024 | Announcement | Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix |
| 17 Jul 2024 | Announcement | Edwards Lifesciences to Host Earnings Conference Call on July 24, 2024 |
| 15 Jul 2024 | Announcement | Edwards Lifesciences to Acquire Innovalve |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |